Regeneron Pre-Announces $102M IPR&D Charge for Q1 2026, Impacting EPS by $0.81

summarizeSummary

Regeneron Pharmaceuticals expects to record a $102 million pre-tax IPR&D charge in Q1 2026, which will reduce diluted EPS by approximately $0.81.

check_boxKey Events

• Pre-Announces Q1 IPR&D Charge

  Regeneron Pharmaceuticals expects to include an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis in its first quarter 2026 financial results.

• Expected EPS Impact

  The IPR&D charge is anticipated to negatively impact both GAAP and non-GAAP net income per diluted share for Q1 2026 by approximately $0.81.

• Charge Originates from Collaborations

  The charge primarily relates to premiums on equity securities purchased, as well as development milestone and up-front payments connected to collaboration and licensing agreements.

• Preliminary Financial Estimates

  The company noted that these results are preliminary, unaudited, and subject to finalization during its financial statement closing procedures.

auto_awesomeAnalysis

Regeneron Pharmaceuticals has pre-announced an approximate $102 million pre-tax acquired in-process research and development (IPR&D) charge for the first quarter of 2026. This charge is expected to negatively impact both GAAP and non-GAAP net income per diluted share by approximately $0.81. While the charge is notable, it stems from collaboration and licensing agreements, which often involve upfront payments or equity premiums for future growth opportunities. Investors should factor this into their Q1 earnings expectations, noting that these are preliminary estimates.